Regen BioPharma Inc (RGBP) Form 10-Q — May 14, 2026
Regen BioPharma Inc reported a net income of $991,927 for the quarter ended March 31, 2026, but this figure is misleading as it is driven entirely by $1.18 million in unrealized derivative income from convertible notes, masking an operating loss of $153,709 on just $59,065 in revenue. The company faces severe liquidity constraints, holding only $271 in cash against a working capital deficit of $5.3 million and an accumulated deficit of $21.6 million. Management explicitly stated there is substantial doubt about the company's ability to continue as a going concern without additional financing.
Key figures
- Revenue
- 59065
- Net Income
- 991927
- Total Debt
- 817717
- Cash Position
- 271
- Shares Outstanding
- 511957643
- Accumulated Deficit
- 21667546
- Lawsuit Claim Amount
- 398740
- Derivative Liability
- 1278763
- Working Capital Deficit
- 5358868
Price after filing
Close on the filing date to close N calendar days later (from $0.00). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.